English Funding Finally Secured For Three Previously Rejected Drugs
Dupixent OKd For A Narrower Indication
Lupin’s repurposed drug Namuscla, Sanofi’s Dupixent and Alnylam’s Givlaari are now deemed to be a cost-effective use of National Health Service resources.
